The plasma EGFR mutation assay can overcome the limitation of tumor tissue availability, shorten the TTI, and facilitate 1st line EGFR-TKI therapy for patients with treatment-naïve stage IV NSCLC, especially in the region of high-prevalence of EGFR mutation. Here, EGFR is linked to non-small cell lung carcinoma.